# Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

> **NCT02637960** · PHASE2,PHASE3 · COMPLETED · sponsor: **Vantia Ltd** · enrollment: 432 (actual)

## Conditions studied

- Nocturia

## Interventions

- **DRUG:** Fedovapagon 2 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02637960
- **Lead sponsor:** Vantia Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-07
- **Final completion:** 2017-08
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02637960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02637960, "Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02637960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*